CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
Seoul, South Korea and 83 other locations
to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...
Phase 2
Seoul, South Korea and 96 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Seoul, South Korea and 84 other locations
Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...
Phase 1
Seoul, Seoul Teugbyeolsi, South Korea and 27 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Seongnam-si, Gyeonggi-do, South Korea and 52 other locations
the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...
Phase 1, Phase 2
Seoul, Seodaemun-gu, South Korea and 30 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Seoul, South Korea and 210 other locations
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer...
Phase 2
Seoul, South Korea and 64 other locations
The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The aims of this study are to see how safe an...
Phase 2
Seoul, Gyeonggi, Korea, Republic of and 51 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
Seoul, South Korea and 50 other locations
Clinical trials
Research sites
Resources
Legal